trial summary · NCT07140315
DK222 Study at Hopkins
An Open-label, Single-center Clinical Trial of [18F]DK222 PET/CT for Imaging of Patients With Non-Small-Cell Lung Cancer (NSCLC) and Urothelial Cancer Who Are Eligible for Treatment With Anti-PD(L)-1
Trial record from the TrialBase DB dataset, status RECRUITING, condition Non-Small Cell Lung Cancer, sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. Facts below are exported values from the current release, not inferred or edited prose.
Summary
The brief summary is the registry's published description, capped for length. Field definitions, types, and provenance rules are in the data dictionary.
This Phase 1 clinical trial will test a new drug called \[18F\]DK222 in people with cancer. The goal is to see if the drug is safe, how it spreads through the body, how long it stays in the body, and how much radiation it gives off. \[18F\]DK222 is designed to attach strongly and specifically to a protein called PD-L1, which helps cancer hide from the immune system. This is a first in human study to collect preliminary safety and toxicity data of \[18F\]DK222.
Source record: https://clinicaltrials.gov/study/NCT07140315
Facts
| registry id | NCT07140315 |
|---|---|
| primary registry | clinicaltrials-gov |
| recruitment status | RECRUITING |
| phase | PHASE1 |
| study type | INTERVENTIONAL |
| lead condition | Non-Small Cell Lung Cancer |
| sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
| sponsor class | OTHER |
| enrollment | 6 |
| start date | 2027-01-31 |
| primary completion | 2028-01-31 |
| completion | 2028-01-31 |
| results posted | not reported |
Conditions
- Non-Small Cell Lung Cancer
- Urothelial Cancer
Interventions
- [18F]DK222 radiotracer
Countries
- United States
Intervention types: DRUG
Work with this record
- Field definitions
Types, scope, and provenance rules for every exported field.
- REST API
Query the same gate-backed records programmatically.
- Evaluation sample
Download a bounded slice before buying.
- $29 API Pass
Seven days of REST and MCP access; credited toward the licence.